-
PROVIDERS
TEMPUS PUBLICATIONS
Browse our latest selection of abstracts, manuscripts, and presentations.
-
LIFE SCIENCES
NEW PRODUCT
xF Monitor: Tumor uninformed treatment response monitoring (TRM) assay for RUO ctDNA detection and quantification
- PATIENTS
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
AI-enabled
precision medicine
Bringing the power of data and artificial intelligence to healthcare.
With the power of AI, we now have the ability to
-
ACCELERATE
the discovery of novel targets
-
PREDICT
the effectiveness of treatments
-
IDENTIFY
potentially life-saving clinical trials
-
DIAGNOSE
multiple diseases earlier
Discover our innovative technology
Explore Tempus
LIFE SCIENCES
We can assist pharmaceutical and biotech companies with better drug development.
Learn More
OUR PLATFORM
We have built a proprietary Platform to make data accessible and deploy AI at scale.
Learn MoreOur Science
Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.
View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
A Pan-cancer Organoid Platform for Precision Medicine
Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers.
Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
Improving patient care through high quality testing, clinical trial matching, and deep research data that powers scientific discovery
50%+ of all Academic Medical Centers in the US are connected to Tempus
50%+ of oncologists in the US connected to Tempus through sequencing, clinical trial matching, and research-enabled partnerships
90% of the top 20 pharma oncology companies partner with Tempus
200+ biopharma partnerships
6,000,000+ de-identified research records to power scientific discovery to improve patient outcomes
26,000+ patients have been identified for potential enrollment into clinical trials in our network
~200 petabytes of data
FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test
The U.S. Food & Drug Administration (FDA) granted Tempus Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test.
READ PRESS RELEASETempus Launches Standalone RNA Sequencing Test, xR
Tempus introduced its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII.
READ PRESS RELEASETempus Announces Broad Launch of Tempus One
Tempus announced the broad launch of Tempus One – the first, AI-enabled clinical assistant that leverages advancements in generative AI to provide clinicians access to patient insights directly at their fingertips.
READ PRESS RELEASEThis is AI-enabled precision medicine
This is the future of healthcare.